Report
MaaT Pharma FIRST LOOK: Presents preclinical MaaT034 data at AACR
MaaT presented new preclinical data on MaaT034, which demonstrate its potential to be a combination therapy alongside immune checkpoint inhibitors to treat solid tumours. First-in-human studies are expected in 2025. Note that MaaT034 is derived from MaaT's donor independent MET-C platform, which can produce microbiome therapies at scale, allowing the company to address larger indications, thus potentially expanding MaaT's commercial opportunity. We reiterate our BUY rating and € 15 TP.
Underlying
MAAT PHARMA SA
Provider
KBC Securities
We are a financial services provider for several types of professional clients, each with distinct needs.
Jacob Mekhael
Other Reports on these Companies
Other Reports from KBC Securities
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.